- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03159598
Drain-Less Abdominally Based Breast Reconstruction Using Lysine-Derived Urethane Adhesive
Drain-Less Abdominally Based Breast Reconstruction Using a Novel Lysine-Derived Urethane Adhesive (TissueGlu, Cohera Medical)
Drains are routinely utilized in breast reconstruction when using abdominal tissue of the patient to remove fluid buildup while the body heals after surgery. However, drains are associated with patient discomfort, anxiety, decreased mobility, increased hospital stays and outpatient visits. Drains can also serve as a site of origin for infection as the system is not completely closed, and infectious organisms could theoretically use the drain as point of entry.
This proposed study investigates a potential novel mechanism to prevent the development of seromas (pockets of clear fluid which can develop after surgery) in patients who undergo breast reconstruction with their own abdominal tissue. By eliminating the required use of a drain, the study team expects patients to have less pain and use less pain medication, as well as more satisfaction with their overall surgical experience.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
Objectives:
- Establish the safety of a lysine-derived urethane adhesive (TissuGlu, Cohera Medical) in patients undergoing autologous abdominal-based breast reconstruction. This will be assessed via analyzing complication profiles of patients post-operatively. The primary endpoints are rate of seroma development, need for seroma drainage and time to drain removal (if in drain group).
- Determine if there is a difference in pain and other quality of life measures when comparing patients who do and do not have abdominal drains. This will be assessed via pain medicine utilization and by delivering a targeted survey pre-operatively, as well as at post-operative day three and four weeks.
Study Design:
Patients will be randomized to one of three arms: 1) Traditional closed-suction drains, 2) TissuGlu with closed-suction drains and 3) TissuGlu without closed-suction drains.
Opintotyyppi
Vaihe
- Ei sovellettavissa
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
Patients undergoing Abdominally-Based Breast Reconstruction
- Both unilateral or bilateral reconstruction is allowed
- Both delayed or immediate reconstruction is allowed
Exclusion Criteria:
- Diabetes
- BMI>30
- Active smokers.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: Tissue Glu with drains
This is standard of care to use Tissue Glu in addition to a drain.
Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities.
Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
|
Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied.
Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
Muut nimet:
Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
Muut nimet:
Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
|
|
Kokeellinen: Tissue Glu without drains
This group utilizes Tissue Glu without the presence of a drain.
Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities.
Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
|
Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied.
Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
Muut nimet:
Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
|
|
Active Comparator: Drains
This is standard of care to use traditional closed-suction drains.
Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities.
Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
|
Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
Muut nimet:
Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Rate of seroma development
Aikaikkuna: Up to 30 days after surgery
|
Number of seromas which develop during the first 30 days after surgery.
|
Up to 30 days after surgery
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Difference in pain between patients with and without abdominal drains
Aikaikkuna: Up to 4 weeks after surgery
|
Patients will be given a questionnaire pre-operatively and the same questionnaire post-operatively.
The change in these questionnaires will be compared between groups
|
Up to 4 weeks after surgery
|
|
Pain Medicine Utilization
Aikaikkuna: Up to 4 weeks after surgery
|
Use of pain medicine after surgery between groups, as indicated by chart review
|
Up to 4 weeks after surgery
|
|
Time to drain removal
Aikaikkuna: Up to 4 weeks after surgery
|
Time from surgery to the removal of the drain for any reason, in patients who were given a drain
|
Up to 4 weeks after surgery
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Andrea Moreira, MD, Cleveland Clinic, Case Comprehensive Cancer Center
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Odotettu)
Ensisijainen valmistuminen (Odotettu)
Opintojen valmistuminen (Odotettu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- CASE5117
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Rintasyöpä
-
Shenzhen Majory Biotechnology Co., Ltd.RekrytointiTriple-negative Breast Cancer (TNBC)Kiina
-
Universidad Europea de MadridEuropean University of Madrid; Hospital Universitario Infanta Leonor; Fundación... ja muut yhteistyökumppanitAktiivinen, ei rekrytointiTriple-negative Breast Cancer (TNBC)Espanja
-
Gangnam Severance HospitalRekrytointiHER2 Rikastettu alatyyppi Breast Cancer, Herzuma, PAM50 -tutkimusKorean tasavalta
-
Shanghai Henlius BiotechEi vielä rekrytointiaRintasyöpä (TNBC (Triple Negative Breast Cancer))Kiina
-
Xijing HospitalAktiivinen, ei rekrytointiRintasyöpä | Rintasyöpä (TNBC (Triple Negative Breast Cancer))Kiina
-
Novartis PharmaceuticalsValmisMetastaattinen rintasyöpä (MBC) | Locally Advance Breast Cancer (LABC)Yhdistynyt kuningaskunta, Espanja
-
Sun Yat-sen UniversityWest China Hospital; First Affiliated Hospital Xi'an Jiaotong UniversityRekrytointiTriple-negative Breast Cancer (TNBC)Kiina
-
Telomir Pharmaceuticals, Inc.Ei vielä rekrytointiaTriple-negative Breast Cancer (TNBC) | Metastaattinen kolminegatiivinen rintasyöpä | Edistynyt kolminkertaisesti negatiivinen rintasyöpä
-
AkesoRekrytointiTriple-negative Breast Cancer (TNBC)Kiina
-
Cancer Institute and Hospital, Chinese Academy...Ei vielä rekrytointiaNeoadjuvanttiterapia | Triple-negative Breast Cancer (TNBC)Kiina
Kliiniset tutkimukset Tissue Glu
-
Afexa Life Sciences IncLopetettuHeikentynyt glukoosinsietoYhdysvallat
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RekrytointiTyypin 1 diabetesYhdysvallat
-
United States Army Research Institute of Environmental...RekrytointiVirtalähde; PuuteYhdysvallat
-
Maastricht University Medical CenterValmisTyypin 2 diabetes mellitusAlankomaat
-
Natural Wellness EgyptValmisTyypin 2 diabetes mellitusEgypti
-
City of Hope Medical CenterNational Cancer Institute (NCI)ValmisBiokemiallisesti toistuva eturauhassyöpäYhdysvallat
-
Jonsson Comprehensive Cancer CenterAktiivinen, ei rekrytointi
-
Jonsson Comprehensive Cancer CenterValmisEturauhasen adenokarsinooma | Toistuva eturauhassyöpäYhdysvallat
-
Jonsson Comprehensive Cancer CenterValmisEturauhasen adenokarsinooma | IV vaiheen eturauhassyöpä AJCC v7 | Vaiheen III eturauhassyöpä AJCC v7 | Vaiheen IIB eturauhassyöpä AJCC v7Yhdysvallat
-
Mayo ClinicPeruutettuMaksasolukarsinoomaYhdysvallat